相关实验视频

Updated: Jun 19, 2025

Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists

Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists

Published on: October 18, 2024

在系统性硬化症相关的血管病变和通过合成前环素类似物抑制中,中性粒细胞细胞外陷的升高

Neda Kortam¹, Wenying Liang¹, Claire Shiple¹

¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, 1150 W Medical Center Drive, Ann Arbor, MI, 48109, USA.

Arthritis research & therapy

|July 25, 2024

概括

中性细胞外细胞陷 (NETs) 与系统性硬化症 (SSc) 中的血管问题有关. простациклин的类似物可能会减少NET的释放,为SSc血管病变提供新的治疗途径.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
血管生物学血管生物学

背景情况:

中性粒细胞和中性粒细胞细胞外陷 (NETs) 涉及各种疾病的血管并发症.
NETs在全身性硬化症 (SSc) 血管病变中的特定作用仍未得到充分研究.
了解NET对SSc血管疾病的贡献,对于开发向疗法至关重要.

研究的目的:

研究系统性硬化症 (SSc) 患者的NET和血管并发症之间的关联.
测试NETs导致SSc血管病变的假设.
评估前环素类似物抑制NET释放和改善SSc血管病变的潜力.

主要方法:

收集了125名SSc患者的血液样本,记录了血管并发症.
利用体外和体外测试来评估循环NET和血管并发症之间的关联.
确定了前环素类似物epoprostenol对SSc患者的NET释放的影响.

主要成果:

与没有血管并发症的SSc患者相比,在SSc患者中观察到中性粒细胞激活和NET释放的增加.
中性粒细胞激活和NET与可溶性E-选择素和VCAM-1正相关,这是血管损伤的标志物.
通过增加中性粒细胞循环AMP,用前环素类似剂治疗减少了数字缺血患者的NET释放.

结论:

在系统性硬化症 (SSc) 中,在NET和血管并发症之间显示出显著的关联.
鉴定出合成的前环素类似物作为潜在的治疗药物,可以减少中性粒细胞过活性和SSc.中的NET释放.
建议在SSc血管病变中使用前环素类型的双重机制:血管扩张和NET形成的抑制.

关键词:

中性粒细胞外细胞陷 (NETs)простациклин 是一种前环素.系统性硬化症系统性硬化症血管并发症血管并发症

更多相关视频

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation

Published on: January 29, 2019

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Published on: August 3, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...